Research and Markets (http://www.researchandmarkets.com/research/mx44rd/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Chronic Heart Failure Overview
  3. Therapeutics Development
  4. Pipeline Products for Chronic Heart Failure - Overview
  5. Pipeline Products for Chronic Heart Failure - Comparative Analysis
  6. Chronic Heart Failure - Therapeutics under Development by Companies
  7. Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes
  8. Chronic Heart Failure - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Chronic Heart Failure - Products under Development by Companies
  13. Chronic Heart Failure - Products under Investigation by Universities/Institutes
  14. Chronic Heart Failure - Companies Involved in Therapeutics Development
  • Amgen Inc.
  • AnGes MG, Inc.
  • ARCA biopharma, Inc.
  • Bayer AG
  • Bial - Portela & Ca, S.A.
  • Caladrius Biosciences, Inc.
  • Capricor Therapeutics, Inc.
  • Celyad SA
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Les Laboratoires Servier SAS
  • Mast Therapeutics, Inc.
  • Mesoblast Limited
  • Novartis AG
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Sanofi
  • Stemedica Cell Technologies, Inc.
  • Vichem Chemie Research Ltd.
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/mx44rd/chronic_heart